Velocys plc (VLS.L), the renewable fuels company, is pleased to announce that it intends to raise approximately £18.4 million (gross) by way of a firm placing and placing and open offer. Highlights: Fund raising of approximately £18.4 million (before expenses): o  Approximately £14 million (before expenses) by way of a firm placing of 139,605,000 New Ordinary Shares (the “Firm Placing Shares”) at a placing price of 10 pence per share (the “Placing Price”) (the “Firm Placing”); and o  £4.4 million (before expenses) by way of an open offer (the “Open Offer”) made to Eligible Shareholders of 44,057,946 New Ordinary Shares (the “Open Offer Shares”)…read more >

RNS Number : 7232C  ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is pleased to announce that, in response to institutional demand, it has completed a fundraise totalling £10 million (before expenses) via a placing of 6,944,445 new ordinary shares of 10p each in the Company (“Ordinary Shares”) at a price of 144p per share (the “Placing Shares”) with new and existing investors (the “Placing”). Key highlights: £10 million (before expenses) raised for the Company via the issue of Placing Shares: · Major new and existing institutional investors have participated in the Placing; and · ImmuPharma will apply these…read more >

Deltex Medical Group plc (“Deltex” or the “Company”)  Placing by way of an accelerated bookbuild and proposed Subscription to raise £1.75 million and Offer to Shareholders to raise up to £350,000  Deltex (AIM: DEMG), announces its intention to undertake an equity placement of £1,064,500 (the “Placing“). The Placing will be effected by way of an accelerated bookbuild, which will be launched immediately following this announcement at a minimum price of 1.25p. Certain other investors are proposing to invest £685,500 in the Company, by way of a subscription at the Issue Price (the “Subscription“). Arden Partners plc (“Arden“) and Turner Pope Investments (TPI)…read more >